Troy Edward Wilson, President and CEO at Kura Oncology, Inc. (KURA), bought 100,000 shares at $12.39 ($1.2M) on 2026-08-24, disclosed to the SEC on 2026-08-24.
Kura Oncology President and CEO Troy Wilson purchased 100,000 shares for $1.24M, marking the largest insider purchase in the company's history. This significant capital commitment by C-suite leadership during a period of strong revenue growth suggests high conviction in the company's pipeline and market position.
The stock has rallied 14.63% over the last 30 days and is currently trading 7.67% below its 52-week high of $12.90, reflecting strong momentum following Q2 earnings.
1) Q2 2026 earnings on August 12, 2026, where the company beat revenue estimates by 23.61%; 2) Publication of preclinical data in Blood on August 18, 2026, highlighting ziftomenib's differentiated binding profile; 3) Analysts project a potential upside of 178.6% based on current price targets.
The stock is highly volatile with a short interest of 15.22% of the float, and recent news indicates a widening net loss of $68.33 million in Q2 2026 despite revenue growth.
Clearly above the average filing.
| Filing → |
| PBYI | SELL | 2026-06-15 | $78K | — | Filing → |
| KURA | SELL | 2025-09-29 | $655K | — | Filing → |
| KURA | BUY | 2025-09-09 | $820K | — | Filing → |